Qiagen NV reported earnings results for the fourth quarter and full year ended December 31, 2014. For the quarter, the company reported adjusted net sales of $360.8 million compared to $362.6 million a year ago. Adjusted operating income was $71.6 million compared to $95.3 million a year ago. Adjusted net income was $60.4 million compared to $79.8 million a year ago. Adjusted diluted EPS was $0.25 compared to $0.33 a year ago. Operating income was $20.6 million compared to $34.0 million in the same period of 2013, with one-time charges taken in both periods related to acquisitions and restructuring initiatives.

For the full year, the company reported adjusted net sales of $1,346.2 million compared to $1,306.3 million a year ago. Adjusted operating income was $312.5 million compared to $318.1 million a year ago. Adjusted net income was $241.1 million compared to $246.3 million a year ago. Adjusted diluted EPS was $1.00 compared to $1.02 a year ago. Operating income was $160.8 million compared to $63.3 million in 2013, with one-time charges taken in both periods for acquisitions and restructuring initiatives. Net income attributable to owners of the company in 2014 was $116.6 million, or $0.48 per diluted share compared to $69.1 million or $0.29 per share in 2013. Net cash provided by operating activities in 2014 rose to $288.0 million from $259.0 million in 2013, with free cash flow increasing to $201.4 million in 2014 compared to $174.5 million in 2013.

For the full year of 2015, the company expects to deliver higher adjusted net sales and adjusted earnings in 2015 at constant exchange rates (CER) with above-market sales growth from the current core portfolio. Adjusted net sales are expected to rise approximately 4% CER, as growth of about 7-8% CER in the core portfolio. Adjusted diluted earnings per share (EPS) are expected to be approximately $1.16 to $1.18 CER compared to $1.00 in 2014.

For the first quarter of 2015, the company expects adjusted net sales growth of approximately 2% CER, which includes approximately 5-6 percentage points of headwind from U.S. HPV sales, and adjusted EPS of approximately $0.22 to $0.23 CER.